ArticleSkin health and disease2026
Evaluating serum procollagen type III N-terminal peptide use as a liver fibrosis screening test in patients with psoriasis receiving methotrexate: a retrospective service evaluation in comparison with the Fibrosis-4 (FIB-4) index.
Article in Skin health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Whilst procollagen type III N-terminal peptide (PIIINP) is recommended as a marker of liver fibrosis in patients with psoriasis on methotrexate, its efficacy is increasingly questioned. PIIINP is not specific as a marker of liver fibrosis, is expensive and has a lengthy turnaround time. There is growing evidence that methotrexate is not a direct cause of liver disease. Fibrosis-4 (FIB-4) is a validated screening score of liver fibrosis that has a substantial weight of evidence. FIB-4 scores are quick to calculate, minimally invasive and cost-effective. Our study reviews PIIINP use versus FIB-4 use in patients with psoriasis about to start or taking methotrexate therapy. This service evaluation demonstrates poor real-world adherence to PIIINP monitoring guidance and a lack of correlation between PIIINP and FIB-4 referral thresholds.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.